HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis.

Abstract
Nephrotoxicity is a major adverse effect of the widely used anticancer drug cisplatin. Oxidative stress, inflammation and apoptosis are implicated in the pathophysiology of cisplatin-induced acute renal injury. Moreover, cisplatin activates many signal transduction pathways involved in cell injury and death, particularly mitogen activated protein kinase (MAPK) pathway. With this background, we aimed to investigate the protective effect of telmisartan, a widely used antihypertensive drug, in cisplatin-induced nephrotoxicity model in rats. To accomplish this, male albino wistar rats (150-200 g) were divided into 6 groups: Normal, cisplatin-control, telmisartan (2.5, 5 and 10 mg/kg) and telmisartan per se treatment groups. Normal saline or telmisartan was administered orally to rats for 10 days and cisplatin was given on 7th day (8 mg/kg; i.p.) to induce nephrotoxicity. On 10th day, rats were killed and both the kidneys were harvested for biochemical, histopathological and molecular studies. Cisplatin injected rats showed depressed renal function, altered proxidant-antioxidant balance and acute tubular necrosis which was significantly normalized by telmisartan co-treatment. Furthermore, cisplatin administration activated MAPK pathway that caused tubular inflammation and apoptosis in rats. Telmisartan treatment significantly prevented MAPK mediated inflammation and apoptosis. Among the three doses studied telmisartan at 10 mg/kg dose showed maximum nephroprotective effect which could be due to maintenance of cellular redox status and inhibition of MAPK activation.
AuthorsSalma Malik, Kapil Suchal, Nanda Gamad, Amit Kumar Dinda, Dharamvir Singh Arya, Jagriti Bhatia
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 748 Pg. 54-60 (Feb 5 2015) ISSN: 1879-0712 [Electronic] Netherlands
PMID25510231 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Benzimidazoles
  • Benzoates
  • Tumor Necrosis Factor-alpha
  • Mitogen-Activated Protein Kinases
  • Cisplatin
  • telmisartan
Topics
  • Animals
  • Antineoplastic Agents (adverse effects)
  • Apoptosis (drug effects)
  • Benzimidazoles (pharmacology, therapeutic use)
  • Benzoates (pharmacology, therapeutic use)
  • Cisplatin (adverse effects)
  • Cytoprotection (drug effects)
  • Enzyme Activation (drug effects)
  • Inflammation (drug therapy, metabolism)
  • Kidney (drug effects, metabolism, pathology, physiopathology)
  • MAP Kinase Signaling System (drug effects)
  • Male
  • Mitogen-Activated Protein Kinases (metabolism)
  • Oxidative Stress (drug effects)
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: